198 published studies and registered trials on the compounds in our catalog, collected worldwide from PubMed, Europe PMC, journal publishers, J-STAGE (Japan), Chinese Biological Abstracts and the ClinicalTrials.gov registry. Each entry links to the original record and notes the study model (in vitro, animal, human or registered trial) and, where it applies, the article language.
Scientific reference onlyCitations are provided for scientific reference only. USAPI products are for research use only and are not for human or veterinary use. The cited studies did not use USAPI products, and no claims are made or implied about USAPI products.
BPC-157 + TB-500 (combination)
Studies that examined BPC-157 and TB-500 together.
Rat Achilles tendon injury model comparing BPC-157, TB-500 and their combination using biomechanical, histopathological and immunohistochemical analyses.
BPC-157
Synthetic pentadecapeptide (BPC 157). Published work is predominantly rodent and in vitro; human data are limited to small uncontrolled reports.
Rat model of surgically transected Achilles tendon examined with functional, macroscopic and histologic measures, with a parallel in vitro assay of cultured tendocytes.
Cell-culture study of rat Achilles tendon fibroblasts examining outgrowth, survival under oxidative stress and migration, along with FAK-paxillin signaling.
Cell-culture study of rat Achilles tendon fibroblasts examining growth hormone receptor expression at the mRNA and protein level and downstream JAK2 signaling.
Angiogenesis assays (chick chorioallantoic membrane, endothelial tube formation) and a rat hind-limb ischemia model examining VEGFR2 expression and signaling.
Lee E et al. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
Retrospective review of patient records from a single clinic describing intra-articular peptide injections in individuals reporting knee pain; uncontrolled, small sample.
Rat model of lower-limb ischemia-reperfusion injury induced by abdominal aortic clamping, with biochemical and histological measures in groups given BPC 157 or saline.
Organ-bath study of residual internal mammary artery segments from bypass surgery, examining vascular tone responses to BPC 157 and the role of endothelial nitric oxide signaling.
Rat model of surgical quadriceps muscle detachment from bone, followed with functional, macroscopic, microscopic and imaging assessments up to 90 days in groups given BPC 157 or control.
Analytical chemistry (in vitro metabolism) — China
Doxorubicin-induced congestive heart failure model in rats and mice comparing BPC 157 with amlodipine and losartan, measuring big endothelin-1 and plasma enzymes. Published in the Journal of Pharmacological Sciences (Japanese Pharmacological Society).
Comparison of PL 14736 (BPC 157) with PDGF-BB in rat sponge-implant granulation tissue and diabetic-mouse excisional wounds, with egr-1 expression studied in Caco-2 cells.
Sikiric P et al. Acta Pharmacol Sin (Zhongguo Yao Li Xue Bao). 2001;22(3):225-230. Europe PMC (CBA 401738)
Rat shock-probe/burying and mouse light/dark behavioral tests comparing BPC-157 with diazepam and saline. Published in Acta Pharmacologica Sinica; record from Chinese Biological Abstracts.
TB-500 is a synthetic peptide related to the actin-binding region of thymosin β4 (Tβ4). Most peer-reviewed literature studies full-length Tβ4 rather than TB-500 itself; studies of TB-500 / Ac-LKKTETQ are mainly analytical (identification, metabolism, anti-doping).
Rat full-thickness dermal wound model examining re-epithelialization, wound contraction, collagen deposition and angiogenesis after topical or intraperitoneal thymosin β4.
Randomized, placebo-controlled, single- and multiple-ascending-dose Phase I study of intravenous synthetic thymosin β4 in healthy volunteers assessing safety, tolerability and pharmacokinetics.
Analytical (mass spectrometry) characterization of commercially sold 'TB500/TB1000' and related products, examining their actual composition versus labeling.
Synthesis and high-resolution mass-spectrometric identification of the N-terminal acetylated 17–23 fragment of thymosin β4 (Ac-LKKTETQ) in a product sold as TB-500.
Study mapping which short peptide sequences within thymosin β4 (including the actin-binding LKKTETQ region) account for its activities in cell and animal assays.
First-in-human randomized, double-blind, placebo-controlled single- and multiple-dose Phase I study of intravenous recombinant human thymosin β4 (NL005) in healthy subjects assessing safety, pharmacokinetics and anti-drug antibodies.
Small multicenter, randomized, double-masked Phase II study of thymosin β4 eye drops (RGN-259) in patients with severe dry eye, assessing safety and ocular signs and symptoms.
Mouse cardiac ischemia/reperfusion and ligation models with in vitro cardiomyocyte assays, plus a clinical cohort of STEMI patients given recombinant human thymosin β4 after PCI.
Peptide chemistry + in vitro (human blood) — Japan
Peptide-synthesis study of deacetyl-thymosin β4 by azide fragment condensation, with in vitro incubation of blood from patients with uremia to examine peripheral T-cell subsets.
Report on a double-blind, placebo-controlled, dose-escalation study of topical thymosin β4 in patients with venous ulcers at 10 sites in Italy and Poland.
Full-thickness dermal wound studies in diabetic (db/db) and aged mice and in rats, comparing thymosin β4 with a synthetic peptide containing its actin-binding domain.
Pharmacological characterization of the pentapeptide ipamorelin, examining growth hormone release selectivity in primary pituitary cells and in anesthetized rats and conscious swine.
Dose-escalation pharmacokinetic/pharmacodynamic modeling study of intravenous infusion in healthy male volunteers, measuring plasma concentrations and growth hormone response.
Proof-of-concept, Phase II, multicenter, double-blind, placebo-controlled study of intravenous ipamorelin in hospital inpatients after small or large bowel resection, examining postoperative ileus measures and safety.
Medicinal-chemistry study describing a series of growth hormone secretagogues derived from the ipamorelin structure and their in vitro and in vivo GH-releasing potency.
Study of young female rats given ipamorelin, GHRH or saline for 21 days, analyzing pituitary somatotroph cell populations and GH content in cell culture.
Rat models of non-inflammatory visceral hypersensitivity and somatic mechanical allodynia comparing ipamorelin with a centrally active ghrelin-receptor agonist.
Anti-doping study identifying urinary metabolites by nano-LC high-resolution mass spectrometry after nasal administration of five GH-releasing peptides, including ipamorelin.
Mass-spectrometric characterization of seized black-market products, identifying a modified GH and glycine-extended GHRP analogues including Gly-ipamorelin.
LC-MS doping-control method for seven peptides in horse plasma, including ipamorelin, CJC-1295 and the TB-500 sequence, plus their in vitro metabolites.
Registered interventional study (Phase 2); registry status: completed; start 2011-04; locations: United States.
CJC-1295 (no DAC) / modified GRF(1-29)
Note: the published CJC-1295 clinical literature studied the DAC (drug affinity complex, albumin-binding) form. USAPI supplies CJC-1295 without DAC (tetrasubstituted GRF(1-29)); the no-DAC form appears mainly in analytical and metabolism studies.
Two randomized, placebo-controlled, double-blind, ascending-dose trials in healthy adults examining pharmacokinetics, GH and IGF-I levels, and safety of CJC-1295 (DAC form).
Registered interventional study (Phase 2); registry status: terminated; start 2005-12.
CJC-1295 (no DAC) + Ipamorelin (blend)
No peer-reviewed study or registered trial of this specific combination was found in PubMed, Europe PMC or ClinicalTrials.gov. Studies of each component are listed in their own sections.
Discovery study identifying MOTS-c, a peptide encoded in mitochondrial 12S rRNA, examining its effects on AMPK signaling in cells and on metabolic parameters in diet-induced obese mice.
Mouse study of physical capacity across ages combined with measurement of circulating and skeletal-muscle MOTS-c levels in humans before and after exercise.
Cross-sectional study measuring circulating MOTS-c levels in obese and normal-weight male children and adolescents in relation to insulin-resistance markers.
Study relating circulating MOTS-c and SHLP2 levels to metabolic syndrome components and depot-specific fat mass (including liver fat) in Chinese and European adults without overt diabetes.
Cross-sectional study of serum MOTS-c in elite athletes, recreationally active and sedentary young men in relation to exercise capacity and antioxidant markers.
Measurement of circulating mitochondrial-derived microproteins, including MOTS-c, at rest and after an acute exercise bout in individuals with cerebral palsy and typically developing controls.
Registered interventional study (Phase 1); registry status: completed; start 2018-07-09; locations: United States. CB4211 is a MOTS-c analogue.
NAD+
Nicotinamide adenine dinucleotide. Most human trials study oral NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) rather than NAD+ itself; these are labeled 'precursor'.
Randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults of the NAD+ precursor nicotinamide riboside, measuring tolerability and blood NAD+ levels.
10-week randomized, placebo-controlled, double-blind trial of the NAD+ precursor nicotinamide mononucleotide in postmenopausal women with prediabetes, measuring insulin sensitivity by clamp.
Randomized, placebo-controlled physiologic study of an oral nicotinamide mononucleotide formulation in overweight or obese adults aged 45+, measuring safety and blood NAD levels.
Prospective randomized, placebo-controlled trial in 120 STEMI patients undergoing primary PCI evaluating intravenous NAD+ as an adjunct, with LVEF at 30 days as the primary endpoint.
Retrospective review of records from a commercial setting comparing infusion time, tolerability and safety markers for intravenous NAD+ versus intravenous nicotinamide riboside.
Cardiomyocyte and mouse study (including SIRT3/SIRT1 knockout and transgenic models) examining exogenous NAD and agonist-induced cardiac hypertrophy signaling.
Double-blind, placebo-controlled Phase I study of intranasal PT-141 in healthy men assessing safety, pharmacokinetics and erectile response measured by RigiScan.
Placebo-controlled study of subcutaneous PT-141 in healthy men and in men with erectile dysfunction, assessing safety, pharmacokinetics and erectile response.
Randomized crossover study in men with erectile dysfunction examining co-administration of intranasal PT-141 with sildenafil versus sildenafil alone or placebo.
Two identical randomized, double-blind, placebo-controlled 24-week Phase III trials (RECONNECT) of bremelanotide in premenopausal women with hypoactive sexual desire disorder.
Randomized, placebo-controlled, double-blind crossover Phase I study in healthy adults examining safety, hemodynamics and pharmacokinetics of bremelanotide co-administered with ethanol.
Two single-centre, randomized, double-blind, placebo-controlled Phase I trials of bremelanotide in premenopausal women with obesity, examining caloric intake and body weight.
Medicinal-chemistry study describing the design of semaglutide (fatty-acid acylation, Aib substitution), receptor potency, albumin binding and pharmacokinetics in animals.
SUSTAIN-6: randomized, double-blind, placebo-controlled trial in adults with type 2 diabetes at high cardiovascular risk evaluating major adverse cardiovascular events.
STEP 1: 68-week randomized, double-blind, placebo-controlled trial in adults with overweight or obesity without diabetes, evaluating change in body weight.
SELECT: randomized, double-blind, placebo-controlled trial in adults with established cardiovascular disease and overweight or obesity without diabetes, evaluating cardiovascular events.
STEP-HFpEF: randomized, double-blind, placebo-controlled trial in adults with heart failure with preserved ejection fraction and obesity, evaluating symptom scores and body weight.
Human — randomized controlled trial (multinational)
SUSTAIN 1: 30-week randomized, double-blind, placebo-controlled Phase III trial of semaglutide monotherapy in adults with type 2 diabetes at 72 sites in nine countries including Canada, Italy, Japan, Mexico, Russia, South Africa and the UK.
Human — randomized controlled trial (multinational)
STEP 2: 68-week randomized, double-blind Phase III trial in adults with overweight or obesity and type 2 diabetes at 149 clinics in 12 countries, evaluating body weight.
Human — Phase III randomized trial (China; article in Chinese, English abstract)
Multicenter, randomized, positive-controlled Phase III equivalence trial of a domestically produced semaglutide injection at 39 centers in China in adults with type 2 diabetes on metformin.
Eight-month study of semaglutide in 65 adults with obesity with or without type 2 diabetes, measuring anthropometrics, blood lipids and adipokines. Published in Kardiologiia (Moscow).
Human — non-randomized controlled study (China; article in Chinese, English abstract)
Prospective non-randomized study of serum metabolomics in adults with obesity, type 2 diabetes and metabolic-associated fatty liver disease given semaglutide.
Human — comparative study (Spain; article in Spanish, English abstract)
52-week randomized, placebo-controlled trial of semaglutide 1 mg weekly in 106 adults with type 2 diabetes and chronic kidney disease, including kidney transcriptomic outcomes.
Double-blind, randomized, placebo-controlled trial (BARI-STEP) of semaglutide 2.4 mg in adults with suboptimal weight loss at least one year after bariatric surgery.
OASIS 2: 68-week double-blind, placebo-controlled Phase 3a trial of oral semaglutide in East Asian adults with overweight or obesity, with or without type 2 diabetes.
PIONEER 11: double-blind, randomized Phase III trial of oral semaglutide monotherapy versus placebo in a predominantly Chinese population with type 2 diabetes.
Discovery study of LY3298176 (tirzepatide) characterizing dual GIP/GLP-1 receptor activity in cell assays and mice, with Phase I studies in healthy subjects and type 2 diabetes.
SURPASS-1: 40-week randomized, double-blind, placebo-controlled Phase III trial in adults with type 2 diabetes managed with diet and exercise alone, evaluating HbA1c.
SURPASS-2: 40-week open-label randomized Phase III trial comparing tirzepatide with semaglutide in adults with type 2 diabetes on metformin, evaluating HbA1c.
SURMOUNT-1: 72-week randomized, double-blind, placebo-controlled Phase III trial in adults with obesity or overweight without diabetes, evaluating body weight.
SURMOUNT-OSA: two randomized, double-blind, placebo-controlled Phase III trials in adults with obstructive sleep apnea and obesity, evaluating apnea–hypopnea index.
SUMMIT: randomized, double-blind, placebo-controlled trial in adults with heart failure with preserved ejection fraction and obesity, evaluating cardiovascular events and symptom scores.
SYNERGY-NASH: Phase II randomized, double-blind, placebo-controlled trial in adults with biopsy-confirmed MASH and liver fibrosis, evaluating liver histology.
Human — randomized controlled trial (multinational)
SURMOUNT-3: randomized, double-blind, placebo-controlled trial in adults with obesity after a 12-week intensive lifestyle run-in, evaluating additional weight change.
Randomized study in 60 Chinese women with overweight or obesity and polycystic ovary syndrome comparing low-dose tirzepatide plus metformin with metformin alone.
Design of SURMOUNT-REAL UK, a 5-year pragmatic randomized trial of tirzepatide plus standard care versus standard care using electronic health records in Greater Manchester.
Discovery study of LY3437943 (retatrutide) characterizing glucagon/GIP/GLP-1 receptor activity in vitro and in obese mice, with a Phase I single-dose study in healthy subjects.
Randomized, double-blind, placebo-controlled multiple-ascending-dose Phase Ib study in people with type 2 diabetes assessing safety, pharmacokinetics and pharmacodynamics.
36-week randomized, double-blind, placebo- and active-controlled Phase II trial in adults with type 2 diabetes conducted in the USA, evaluating HbA1c and body weight.
Randomized, double-blind, placebo-controlled substudy of the Phase II obesity trial in participants with metabolic dysfunction-associated steatotic liver disease, evaluating liver fat by MRI.
Phase III randomized, double-blind, placebo-controlled 80-week trial in adults with obesity without diabetes, evaluating body weight and knee osteoarthritis pain scores.
TRIUMPH-4 and TRIUMPH-1-OA: Phase 3 randomized, placebo-controlled trials of once-weekly retatrutide in adults with knee osteoarthritis pain and BMI of 27 or more.
40-week Phase 3 randomized, double-blind, placebo-controlled trial of retatrutide in adults with type 2 diabetes managed by diet and exercise, at 48 sites in the USA, Mexico and India.
ClinicalTrials.gov · Phase 3 · Active not recruiting · first posted 2024. NCT06662383
Registered interventional study (Phase 3); registry status: active not recruiting; start 2024-11-01; locations: Argentina, Germany, Poland, Puerto Rico, United States.
ClinicalTrials.gov · Phase 3 · Active not recruiting · first posted 2024. NCT06383390
Registered interventional study (Phase 3); registry status: active not recruiting; start 2024-04-30; locations: Argentina, Australia, Austria, Belgium, Brazil, Canada and others.
Citation details (title, first author, journal, year, PMID, DOI, registry ID) were retrieved from PubMed / NCBI, Europe PMC and ClinicalTrials.gov and cross-checked against Crossref or the publisher record. Non-English articles are listed under their English titles. Study descriptions summarize design only and are not statements about any USAPI product. USAPI products are sold strictly for in-vitro laboratory research by qualified researchers aged 21+.
USAPIPeptides
Age & research verification
This site supplies research chemicals to researchers aged 21 or older. Enter your date of birth to continue.